QUESTIONS & ANSWERS
Labcorp’s Dr. Brian Caveney conducted a fireside chat with Dr. Carlos Cordon-Cardo of Mount Sinai Health System.
Brian Caveney, MD
Chief Medical Officer and President, Labcorp Diagnostics
Carlos Cordon-Cardon, MD, PhD
Irene Heinz Given and John LaPorte Given Professor and Chairman, Mount Sinai Health System Department of Pathology
Dr. Caveney: What was it like in those early days of the pandemic, with New York City the absolute epicenter of the world in terms of numbers and not knowing exactly what was going on?
Dr. Caveney: Mount Sinai has long been a world leader in microbiology and immunology research. Tell us about some of the early antibody research into the immune system response to COVID-19.
Dr. Caveney: Do you believe that one silver lining from the pandemic is that we will have a stronger public health system and perhaps do more genomic surveillance of pathogens over time? Do you think that monitoring specimens over time will give us a better sense of how these viruses and other pathogens are mutating, and how perhaps the treatment in vaccines need to also change over time so that we can present a better defense to them?
Dr. Caveney: While the pandemic affected the way all of us work, live and play, it also directly impacted the way pathologists work. Pre-COVID, Labcorp was working with Mount Sinai on a variety of different digital pathology initiatives to digitize the slidemaking process. Do you think that the pandemic will accelerate the transition to digital pathology?
Dr. Caveney: You’ve said that the healthcare system, the public, the government, and others now realize the importance and the value of an accurate and timely diagnosis at the beginning of clinical care, so that all of the right downstream clinical treatment decisions can be made. Perhaps doctors and others will remember how important pathology and laboratory medicine was during the pandemic and give it its credit.